Broadcom Inc. $AVGO Shares Purchased by First Bank & Trust MarketBeat

Myecfo LLC Takes Position in Broadcom Inc. $AVGO MarketBeat

Stokes Capital Advisors LLC Sells 7,165 Shares of Broadcom Inc. $AVGO MarketBeat

National Wealth Management Group LLC Has $1.81 Million Position in Broadcom Inc. $AVGO marketbeat.com

Broadcom Inc. $AVGO Shares Purchased by First Bank & Trust marketbeat.com

Myecfo LLC Takes Position in Broadcom Inc. $AVGO marketbeat.com

Stokes Capital Advisors LLC Sells 7,165 Shares of Broadcom Inc. $AVGO marketbeat.com

NVIDIA Corporation $NVDA Shares Sold by Scott & Selber Inc. marketbeat.com

LVM Capital Management Ltd. MI Has $83.10 Million Stake in Broadcom Inc. $AVGO MarketBeat

Broadcom Inc. $AVGO is PUREfi Wealth LLC's 6th Largest Position MarketBeat

Broadcom Inc. $AVGO Holdings Cut by First Merchants Corp MarketBeat

Broadcom Inc. $AVGO Shares Sold by HWG Holdings LP MarketBeat

SeaCrest Wealth Management LLC Lowers Stock Holdings in Broadcom Inc. $AVGO MarketBeat

Heartwood Wealth Advisors LLC Boosts Holdings in Broadcom Inc. $AVGO MarketBeat

Sax Wealth Advisors LLC Increases Stock Holdings in Alphabet Inc. $GOOG MarketBeat

LVM Capital Management Ltd. MI Has $83.10 Million Stake in Broadcom Inc. $AVGO marketbeat.com

Broadcom Inc. $AVGO is PUREfi Wealth LLC's 6th Largest Position marketbeat.com

Broadcom Inc. $AVGO Shares Sold by HWG Holdings LP marketbeat.com

Broadcom Inc. $AVGO Holdings Cut by First Merchants Corp marketbeat.com

Heartwood Wealth Advisors LLC Boosts Holdings in Broadcom Inc. $AVGO marketbeat.com

SeaCrest Wealth Management LLC Lowers Stock Holdings in Broadcom Inc. $AVGO marketbeat.com

Sax Wealth Advisors LLC Increases Stock Holdings in Alphabet Inc. $GOOG marketbeat.com

NVIDIA Corporation $NVDA Shares Sold by Scott & Selber Inc. MarketBeat

Key PointsHyperscalers are spending hundreds of billions on new data center build-outs.

Key PointsThe U.S. Navy just awarded General Dynamics $15.4 billion to support construction of 12 nuclear submarines.

一家A股上市逾15年、多年无实际控制人的上市公司，可能要迎来真正的“老板”了。它就是疫苗龙头沃森生物。 近日，疫苗龙头沃森生物发布公告提到，该公司正在推进一项募集资金不超过20.03亿元的定增方案，世纪金源旗下腾云新沃将全额认购定增的股份。 如果交易最终落地，沃森生物将结束上市以来长达15年之久的“无主”局面，而有着“资本运作高手”之称的黄涛或通过定增成为其新实控人。 世纪金源是一家综合性跨行业的国际企业集团，旗下形成了“大消费、大文旅、大健康、新科技”四大主航道业务。2018年，黄涛从其父亲黄如论手中接手世纪金源。接班后，黄涛在资本市场动作不断，从皖通科技到安奈儿，此番再度跨界布局生物医药赛道，让黄氏家族在A股的资本版图进一步扩大。 当投资者们热捧以AI为代表的科技股，冷门许久的疫苗股却被敏锐的资本看上。沃森生物，有什么吸引点？ 多年无实控人，公司业绩承压 沃森生物是一家专业从事人用疫苗且集研发、生产、销售于一体的生物制药企业。2010年11月，公司登陆创业板，至今上市时间超过15年。 沃森生物重要股东刘俊辉和李云春的持股比例曾分别达到11.39%、15.05%，经过连续减持，截至2025年三季度末，两人的持股比例均不足2%。 沃森生物工作人员曾坦言， 公司自成立时起即为无实际控制人的股权结构。 从经营看， 过去几年，沃森生物的业绩整体承压。 2021年，沃森生物的营收同比增长17.82%，归母净利润同比下降57.36%，业绩“增收不增利”。研发费用增加及产生公允价值变动损失，拖累了当年利润。 2022年，沃森生物的业绩反弹，营收同比增长46.89%，归母净利润同比增长70.35%。 2023年，沃森生物营收同比下降19.12%，归母净利润同比下降42.44%，营收净利双降的原因包括13价肺炎球菌多糖结合疫苗产品销售量同比下降、双价人乳头瘤病毒疫苗(毕赤酵母)销售量未达预期等。 2024年，沃森生物的营收同比下降31.41%，归母净利润同比下降66.10%。2025年业绩预告显示，归母净利润同比增长13%至34%，但扣非后净利润依旧同比下降9%至22%。营收端方面，预计疫苗产品总收入同比下降约8%。除了公司近年来的业绩承压外，公司长期以来高度分散的股权“无主”的情况却带来了治理上的隐患。 比如，2024年11月，沃森生物在一项涉及子公司少数股权转让的议案未能通过，...

Capital One Financial enters 2026 at a critical juncture, as its Discover acquisition and rising credit risks test its ability to deliver sustained growth.

Meta Platforms, Inc. $META Stock Position Reduced by HWG Holdings LP marketbeat.com

Meta Platforms, Inc. $META Stock Position Reduced by HWG Holdings LP MarketBeat

Sax Wealth Advisors LLC Has $5.29 Million Holdings in Meta Platforms, Inc. $META marketbeat.com